Advertisement
Advertisement

ATRA

ATRA logo

Atara Biotherapeutics, Inc

5.20
USD
Sponsored
-0.31
-5.72%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

5.13

-0.07
-1.35%

ATRA Earnings Reports

Positive Surprise Ratio

ATRA beat 19 of 40 last estimates.

48%

Next Report

Date of Next Report
Mar 05, 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.72M
/
-$0.44
Implied change from Q3 25 (Revenue/ EPS)
-21.09%
/
+37.50%
Implied change from Q4 24 (Revenue/ EPS)
-91.68%
/
-63.03%

Atara Biotherapeutics, Inc earnings per share and revenue

On Nov 12, 2025, ATRA reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.87 USD, resulting in a 63.52% surprise. Revenue reached 3.45 million, compared to an expected 1.43 million, with a 142.21% difference. The market reacted with a -0.72% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.44 USD, with revenue projected to reach 2.72 million USD, implying an increase of 37.50% EPS, and decrease of -21.09% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Atara Biotherapeutics, Inc reported EPS of -$0.32, beating estimates by 63.52%, and revenue of $3.45M, 142.21% above expectations.
The stock price moved down -0.72%, changed from $12.56 before the earnings release to $12.47 the day after.
The next earning report is scheduled for Mar 05, 2026.
Based on 6 analysts, Atara Biotherapeutics, Inc is expected to report EPS of -$0.44 and revenue of $2.72M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement